RT Journal Article
T1 Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu
A1 Jose Garcia, Maria
A1 Rivero, Montserrat
A1 Miranda-Bautista, Jose
A1 Baston-Rey, Iria
A1 Mesonero, Francisco
A1 Leo-Carnerero, Eduardo
A1 Casas-Deza, Diego
A1 Cagigas Fernandez, Carmen
A1 Martin-Cardona, Albert
A1 El Hajra, Ismael
A1 Hernandez-Aretxabaleta, Nerea
A1 Perez-Martinez, Isabel
A1 Fuentes-Valenzuela, Esteban
A1 Jimenez, Nuria
A1 Rubin de Celix, Cristina
A1 Gutierrez, Ana
A1 Suarez Ferrer, Cristina
A1 Maria Huguet, Jose
A1 Fernandez-Clotet, Agnes
A1 Gonzalez-Vivo, Maria
A1 Del Val, Blanca
A1 Castro-Poceiro, Jesus
A1 Melcarne, Luigi
A1 Duenas, Carmen
A1 Izquierdo, Marta
A1 Monfort, David
A1 Bouhmidi, Abdel
A1 Ramirez De la Piscina, Patricia
A1 Romero, Eva
A1 Molina, Gema
A1 Zorrilla, Jaime
A1 Calvino-Suarez, Cristina
A1 Sanchez, Eugenia
A1 Nunez, Andrea
A1 Sierra, Olivia
A1 Castro, Beatriz
A1 Zabana, Yamile
A1 Gonzalez-Partida, Irene
A1 De la Maza, Saioa
A1 Castano, Andres
A1 Najera-Munoz, Rodrigo
A1 Sanchez-Guillen, Luis
A1 Castro, Micaela Riat
A1 Luis Rueda, Jose
A1 Manuel Benitez, Jose
A1 Delgado-Guillena, Pedro
A1 Tardillo, Carlos
A1 Pena, Elena
A1 Frago-Larramona, Santiago
A1 Carmen Rodriguez-Grau, Maria
A1 Plaza, Rocio
A1 Perez-Galindo, Pablo
A1 Martinez-Cadilla, Jesus
A1 Menchen, Luis
A1 Barreiro-De Acosta, Manuel
A1 Sanchez-Aldehuelo, Ruben
A1 Dolores De la Cruz, Maria
A1 Javier Lamuela, Luis
A1 Marin, Ignacio
A1 Nieto-Garcia, Laura
A1 Lopez-San Roman, Antonio
A1 Manuel Herrera, Jose
A1 Chaparro, Maria
A1 Gisbert, Javier P.
A1 Young Grp GETECCU, 
K1 inflammatory bowel disease
K1 Crohn's disease
K1 ulcerative colitis
K1 anti-TNF
K1 ustekinumab
K1 vedolizumab
K1 postoperative complications
K1 surgery
K1 preoperative therapy
K1 Postoperative infectious complications
K1 Preoperative steroid use
K1 Crohns-disease
K1 Ulcerative-colitis
K1 Risk-factors
K1 Gastrointestinal surgery
K1 Surgical complications
K1 Outcomes
K1 Metaanalysis
K1 Resection
AB Background: The impact of biologics on the risk of postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack of evidence is more relevant for ustekinumab and vedolizumab. Aims: To evaluate the impact of biologics on the risk of PC. Methods: A retrospective study was performed in 37 centres. Patients treated with biologics within 12 weeks before surgery were considered "exposed". The impact of the exposure on the risk of 30-day PC and the risk of infections was assessed by logistic regression and propensity score-matched analysis. Results: A total of 1535 surgeries were performed on 1370 patients. Of them, 711 surgeries were conducted in the exposed cohort (584 anti-TNE 58 vedolizumab and 69 ustekinumab). In the multivariate analysis, male gender (OR: 1.5; 95% CI: 1.2-2.0), urgent surgery (OR: 1.6; 95% CI: 1.2-2.2), laparotomy approach (OR: 1.5; 95% CI: 1.1-1.9) and severe anaemia (OR: 1.8; 95% CI: 1.3-2.6) had higher risk of PC, while academic hospitals had significantly lower risk. Exposure to biologics (either anti-TNF, vedolizumab or ustekinumab) did not increase the risk of PC (OR: 1.2; 95% CI: 0.97-1.58), although it could be a risk factor for postoperative infections (OR 1.5; 95% CI: 1.03-2.27). Conclusions: Preoperative administration of biologics does not seem to be a risk factor for overall PC, although it may be so for postoperative infections.
PB Mdpi
YR 2021
FD 2021-10-01
LK http://hdl.handle.net/10668/19289
UL http://hdl.handle.net/10668/19289
LA en
DS RISalud
RD Apr 8, 2025